Questions discussed in this category
Patient has had previous failure of methotrexate. Would you switch to alternative (TNFi or Rituximab) or continue abatacept with regular dermatology...
Does your choice of DMARD/biologics change due to increased risk of malignancy?
Patient with dermatomyositis on rituximab with refractory inflammatory arthritis. Intolerant of traditional DMARDs such as methotrexate, leflunomide, ...
Are there any instances where you would prefer a biosimilar rather than the reference product?
21411214621903520109135551266415818149611590414141117801218912130118611174788788845873986508061
Papers discussed in this category
Arthritis care & research, 2012-05
Arthritis Rheumatol, 2016 Jan
N Engl J Med,
Mediterr J Rheumatol, 2020 Jun 11
Curr Med Chem,
Pathology, 2017 Mar 11
Front Immunol, 2021 Jul 14
Arthritis & rheumatology (Hoboken, N.J.), 2018-03
Arthritis and rheumatism, 2011-03
The Journal of rheumatology, 2013-05
JAMA internal medicine, 2017 Nov 01
Annals of the rheumatic diseases, 2024 Jan 11